Catalog No.
PHB87001
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human MOS (Ser54-Gly346).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Proto-oncogene serine/threonine-protein kinase mos, 2.7.11.1, Oocyte maturation factor mos, Proto-oncogene c-Mos, MOS
Purification
Purified by antigen affinity column.
Accession
P00540
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis., PMID:40481442
Adebrelimab in Small Cell Lung Cancer: From Current Advances to Emerging Combination Strategy and Challenge., PMID:40475251
Ultrasensitive Analysis of BRCA-1 Based on Gold Nanoparticles and Molybdenum Disulfide Electrochemical Immunosensor with Enhanced Signal Amplification., PMID:40422069
Clinical benefit of continuation of PD-1 inhibitors after progression on first-line chemoimmunotherapy in metastatic gastric cancer and biomarker exploration., PMID:40413463
Efficacy and safety of finotonlimab plus docetaxel vs. docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trial., PMID:40386729
Two-Dimensional MoS2 Field-Effect Biosensor for Highly Sensitive Detection of Cardiac Troponin I., PMID:40377210
Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study., PMID:40293533
Sensitive amperometric immunosensor for pathogen antigen based on MoS2@AuNPs assembling dual-peptide as bioprobes with significant dual signal amplification., PMID:40274335
Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin., PMID:40252634
NMR and mass spectral studies of 'Abaliose' - a novel hexasaccharide isolated from Bubalus bubalis milk., PMID:40235386
The efficacy and safety of PD-1/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, HER2-negative gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials., PMID:40207218
Coaxially fabricated electrospinning near-infrared light-responsive nanofibrous membranes for combating drug-resistant bacteria., PMID:40199072
A novel optical fiber immunosensor for detection of heart failure marker ST2 based on MoS2-modified D-shaped ExTFG., PMID:40120516
PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer., PMID:40116923
Efficacy and safety of arterial FOLFOX chemotherapy plus anti-PD-(L)1 immunotherapy as a first-line treatment for unresectable intrahepatic cholangiocarcinoma: a propensity score matching analysis., PMID:40115910
Avelumab Maintenance Therapy in Advanced Urothelial Carcinoma: Implications of Timing and Treatment Sequencing., PMID:40075745
Efficacy and safety of disitamab vedotin in combination with immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma., PMID:40057923
Efficacy and safety analysis of atezolizumab continuation beyond progression in extensive-stage small cell lung cancer., PMID:40038111
Efficacy and safety of sintilimab combined with trastuzumab and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction cancer., PMID:40028325
The effectiveness and safety of RC48 alone or in combination with PD-1 inhibitors for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study., PMID:40022107
Long-Term Immune Consequences of Initial SARS-CoV-2 A.23.1 Exposure: A Longitudinal Study of Antibody Responses and Cross-Neutralization in a Ugandan Cohort., PMID:40006690
Sensitive Competitive Electrochemical Immunosensor for Hg (II) Based on Molybdenum Disulfide/Reduced Graphene Oxide/Gold Nanocomposites., PMID:39943262
The Association Between Tumor Burden and the Efficacy of Immunotherapy Among Patients With Non-small Cell Lung Cancer., PMID:39938068
Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence., PMID:39907049
Comparative efficacy of cetuximab combined with FOLFOX or CAPEOX in first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer: a multicenter case-control study., PMID:39903643
Bioinspired rational spatial-arrangement of antigens enables the accurate and rapid detection of anti-p53 autoantibody., PMID:39890668
Modeling Sporadic Progressive Supranuclear Palsy in 3D Midbrain Organoids: Recapitulating Disease Features for In Vitro Diagnosis and Drug Discovery., PMID:39876539
[Efficacy and safety of transarterial chemoembolization combined with sintilimab and bevacizumab biosimilar for unresectable hepatocellular carcinoma]., PMID:39863560
The Rare Entity of Basaloid Thymic Carcinoma: A Multicentric Retrospective Analysis from the Italian Collaborative Group for ThYmic MalignanciEs (TYME)., PMID:39858021
Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study., PMID:39850887
Follow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study-FLORA., PMID:39842244
Polyphenol-modified 3D Nanoassemblies: A novel antibacterial immunoglobulins loading platform for rapid detection of Salmonella typhimurium., PMID:39826525
Clinical Characteristics of and Treatment Pattern for EGFR-Amplified Colorectal Cancer., PMID:39810491
Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3-year survival update and multi-omics analysis., PMID:39757723
Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53., PMID:39736248
Bovine Serum Albumin-Capped Fluorescent Copper Nanocluster Incorporated with 2D-Molybdenum Disulfide Nanosheets as a FRET-Based Immune Probe for the "Turn-On" Detection of cTnT., PMID:39727303
Humoral correlate of vaccine-mediated protection from tuberculosis identified in humans and non-human primates., PMID:39713388
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016., PMID:39700681
[A prospective phase Ⅱ clinical trial of toripalimab combined with platinum-based concurrent chemoradiotherapy and consolidation chemotherapy in patients with locally advanced cervical cancer]., PMID:39690535
Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study., PMID:39690337
Effective inhibition of dengue virus replication using 3'UTR-targeted Vivo-Morpholinos., PMID:39676860
Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study., PMID:39672785
Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial., PMID:39668159
Real-World Treatment Patterns and Clinical Outcomes in Patients With Locally Advanced or Metastatic Urothelial Carcinoma by Eligibility for Maintenance Avelumab., PMID:39662152
Clinicopathological characteristics, evolution, and treatment outcomes of hormone receptor-negative/HER2-low metastatic breast cancer: a pooled analysis of individual patient data from three prospective clinical trials., PMID:39640887
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors., PMID:39637943
Gemcitabine Cisplatin and Durvalumab Experience in Advanced Biliary Tract Cancers: A Real-World, Multicentric Data From India., PMID:39637344
Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trials., PMID:39612560
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study., PMID:39603144
Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas., PMID:39572979
For research use only. Not for human or drug use.
